wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41522586-4B7AEF06-0DFE-4351-87AC-D947F28F4783
Q41522586-4B7AEF06-0DFE-4351-87AC-D947F28F4783
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41522586-4B7AEF06-0DFE-4351-87AC-D947F28F4783
Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant.
P2860
Q41522586-4B7AEF06-0DFE-4351-87AC-D947F28F4783
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41522586-4B7AEF06-0DFE-4351-87AC-D947F28F4783
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d428d47758af8573efe6cfe49532cc784d65149c
P2860
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.